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The recent ﬁndings that adult stem cells are capable of generating new blood vessels and parenchymal cells within
tissues they have colonized has raised immense optimism that these cells may provide functional recovery of
damaged organs. The use of adult stem cells for regenerative therapy poses the challenging task of getting these
cells into the requisite sites with minimum morbidity and maximum efﬁciency. Ideally, tissue-speciﬁc colonization
could be achieved by introducing the stem cells intravascularly and exploiting the native physiologic processes
governing cell trafﬁcking. Critical to the success of this approach is the use of stem cells bearing appropriate
membrane molecules that mediate homing from vascular to tissue compartments. Hematopoietic stem cells (HSC)
express a novel glycoform of CD44 known as hematopoietic cell E-/L-selectin ligand (HCELL). This molecule is the
most potent E-selectin ligand natively expressed on any human cell. This article reviews our current understanding
of the molecular basis of HSC homing and will describe the fundamental ‘‘roll’’ of HCELL in opening the avenues for
efﬁcient HSC trafﬁcking to the bone marrow, the skin and other extramedullary sites.
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Substantial evidence has accumulated over the past several
years that ‘‘adult’’ (i.e., postnatal) stem cells are capable of
generating cells not only of their usual somatic lineage but
also, depending on where they reside, that of diverse
tissues/organs (Azizi et al, 1998; Orlic et al, 2001; Hess et al,
2002; Hofstetter et al, 2002; Jin et al, 2002; Toma et al,
2002; Hess et al, 2003). Although it is debated whether this
effect is due to stem cell ‘‘plasticity’’ (the capacity to
transdifferentiate across typical lineage commitments, even
across derivative embryonic layers) or due to fusion and
provoked proliferation of resident tissue-specific cells
(Wulf et al, 2001; Terada et al, 2002; Ianus et al, 2003;
Vassilopoulos et al, 2003), it is indisputable that remarkable
new blood vessel and tissue growth can occur. Justifiably,
these findings have engendered great hope that adult stem
cells will prove useful in curing previously incurable illnesses
affecting millions of people across all ages.
The most plentiful source of adult stem cells in the body
is the bone marrow. Two populations of stem cells are
marrow residents: the hematopoietic stem cells (HSC) and
the non-hematopoietic mesenchymal stem cells (MSCs).
Both of these have broad developmental potential and
display ‘‘plasticity’’ (Caplan and Dennis, 1996; Wulf et al,
2001; Jiang et al, 2002a, b). MSCs are relatively rare in situ
and must be expanded in culture to achieve sufficient
numbers, whereas bone marrow natively contains large
numbers of HSC. HSC can be obtained readily by direct
extraction (harvesting) or by cytokine-stimulated mobiliza-
tion of the cells into the circulation with subsequent
collection by pheresis, and the techniques for collection
and processing of highly enriched populations of HSC are
clinically routine. Thus, ex vivo expansion of HSC is not
required, and these cells are imminently available. A major
issue still facing the clinical use of HSC for regenerative
therapy, however, is how to achieve sufficient colonization
of these cells within the relevant site(s) of tissue damage.
Although the direct injection of HSC has already shown
promise in recovery of blood supply and function in
ischemic heart disease in rodent models (Orlic et al, 2001)
and in humans (Stamm et al, 2003; Tse et al, 2003), this
approach is hampered by the need to specifically map
affected zones and to perform invasive procedure(s).
Clearly, the cost(s) of these intervention(s) and risk(s) of
procedure-related morbidity must always be considered.
Moreover, in general, direct injection is only feasible for
affected organs/tissues with distinct margins and anatomic
localization. An alternative method to achieve tissue
infiltration is to introduce HSC into the systemic circulation
thereby relying on physiologic homing to deliver the cells to
the relevant site(s). This approach has already shown
promise in preclinical models of stroke and myocardial
infarction (Chen et al, 2001; Wang et al, 2001). In particular,
for regeneration of large tissue areas such as skin affected
by burns or by autoimmune or congenital/genetic degen-
erative disease(s), the requisite colonization of stem cells
could only be accomplished through a systemic approach.
Abbreviations: CLA, cutaneous lymphocyte antigen; HCELL,
hematopoietic cell E-/L-selectin ligand; HEV, high endothelial
venules; HSC, Hematopoietic stem cells; mAb, monoclonal
antibodies; PSGL-1, P-selectin glycoprotein ligand-1
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To migrate to tissue(s), all circulating cells must first be
capable of adhering to vascular endothelium with sufficient
strength to overcome the shear forces of blood flow in a
process known as ‘‘rolling’’. This primary adhesive interac-
tion dictates the trafficking of blood-borne cells to any
tissue. Accordingly, to attain successful tissue colonization
of infused stem cells requires that this process be
functionally intact and, preferably, optimized. This review
will consider this issue, and will discuss the emerging
evidence that a newly discovered E-selectin ligand, hema-
topoietic cell E-/L-selectin ligand (HCELL), may function as
the principal ‘‘homing receptor’’ directing migration of HSC
to the bone marrow, the skin and other extramedullary sites
of tissue injury/inflammation.
What Is a ‘‘Homing’’ Receptor?
The term ‘‘homing receptor’’ is an historical, operational
definition, first coined to describe the migration patterns of
circulating lymphocytes (Gowans, 1957, 1959; Gowans and
Steer, 1980). Early studies in rodent and sheep models
demonstrated that lymphocyte migration to lymphoid
tissues was conspicuously non-random: lymphocytes iso-
lated from intestinal lymph tended to migrate through gut-
associated lymphoid tissues whereas lymphocytes isolated
from peripheral lymph node tended to migrate to those sites
(reviewed in Chin et al, 1991). Later it became clear that
specificity in migration to different lymphoid compartments
depended on the ability of circulating lymphocytes to bind
to the specialized post-capillary venules of lymph nodes
known as ‘‘high endothelial venules’’ (HEV). Monoclonal
antibodies (mAb) were raised against lymphocyte mem-
brane glycoproteins that mediated high affinity adhesion to
lymphoid organ-specific HEV ligand(s), and these mAb
blocked the migration of lymphocytes to peripheral lymph
nodes and Peyer’s patches (Gallatin et al, 1983; Rasmussen
et al, 1985; Chin et al, 1986; Woodruff et al, 1987; Holzmann
et al, 1989). These functionally defined homing receptors
were then characterized at a molecular level. The biochem-
ical studies revealed that the principal peripheral lymph
node homing receptor was a molecule of the selectin class
of adhesion molecules named ‘‘L-selectin’’, whereas the
homing receptor for gut-associated lymphoid tissue was
another structure of the integrin class called a4b7 (LPAM-1).
Had it not been for the fact that L-selectin expression is
not restricted to lymphocytes, our understanding of tissue-
specific homing would have been complete two decades
ago. But it was soon clear that all mature leukocytes and, in
fact, primitive hematopoietic progenitor cells (but not
intermediate differentiating myeloid or lymphoid cells),
characteristically express L-selectin (Sackstein, 1993).
Importantly, in vitro adherence assays under shear condi-
tions showed that L-selectin expressed on neutrophils was
capable of directing the binding of these cells to HEV
ligands (Lawrence et al, 1995), yet these cells do not
routinely migrate into lymph nodes. These findings raised
doubts about the function of L-selectin as the lymph node
homing receptor: How could a molecule serve as a homing
receptor on one cell and not another? This puzzle was
solved with the understanding that physiologic migration of
blood-borne cells into tissues requires a cascade of multiple
steps.
Leukocytes typically exit the vasculature at post-capillary
venules, where shear stress ranges from 1 to 4 dynes per
cm2 (Jones et al, 1996). In this state of motion, leukocytes
must first make contact along the endothelial surface with
adhesive interactions of sufficient strength to overcome the
shear forces of blood flow (initial tethering and rolling, Step
1; see Fig 1). During this initial stage, leukocytes are
exposed to chemical signals (chemokines, cytokines, and
other pro-inflammatory mediators) in the local milieu (Step
2), thereby leading to activation-dependent upregulation of
integrin adhesive capabilities resulting in firm arrest (Step 3).
Firm arrest is then followed by transmigration (Step 4) (see
Fig 1). This ‘‘multi-step paradigm’’ (Butcher, 1991; Springer,
1994) holds that cells capable of homing to any given tissue
must possess the capacity to crawl along the endothelium
with sufficient time to ‘‘taste’’ the local milieu and must
possess the requisite receptors for the environmental
chemoattractants such as chemokines, thus leading to
activation-induced upregulation of the surface integrins
mediating firm adherence. Chemokines are a superfamily of
small proteins that function as potent chemotactic agents,
some of which have a tissue- and inflammation-specific
distribution, and others which are widely distributed (Camp-
bell and Butcher, 2000; Moser and Loetscher, 2001;
D’Ambrosio et al, 2003). The activation signal(s) for firm
adherence are typically mediated by G-protein-coupled
chemokine receptors, which have a cell-specific distribu-
tion. For the case of lymphocyte homing to peripheral lymph
nodes, HEV constitutively express the chemokine SLC
(CCL21) that binds the lymphocyte receptor known as
CCR7 (Gunn et al, 1998; Tangemann et al, 1998; Willimann
et al, 1998). Neutrophils do not express CCR7, and,
therefore, while able to undergo rolling interactions on
HEV, they cannot convert these contacts into firm adher-
ence (Warnock et al, 1998). This example emphasizes the
fact that the ‘‘address’’ directing cellular trafficking to
relevant tissues is created by the combined expression of
Figure1
The multi-step model of leukocyte–endothelial interactions. Sche-
matic representation of the multiple steps involved in leukocyte
migration from vascular to tissue components. Steps 1a and b together
act to ‘‘arrest’’ cells in flow and are mediated principally by selectin–
ligand interactions. Chemokine-induced activation (Step 2) of integrin
adhesiveness results in firm adherence (Step 3) followed by transmi-
gration (Step 4). See text for details.
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leukocyte and endothelial adhesion molecules and their
respective chemokine receptors and chemokines.
Although the appropriate display of chemokines and
chemokine receptors is required for passage through the
endothelium, no cellular emigration from the vascular
compartment can occur without the initial (Step 1) mole-
cular adhesive interactions that cause decelerative braking
(‘‘tethering’’) of the flowing cells and organized sustained
contact (‘‘rolling’’) of these cells against the endothelial
surface. These critical contacts are created by leukocyte
surface molecules possessing the requisite chemical
characteristics to achieve fast on-off bond times with their
respective endothelial co-receptors; in the setting of fluid
shear forces and consequent cellular torque, this translates
into a rolling interaction (Lawrence et al, 1997). Thus, Step 1
is the physiologic linchpin for all downstream events and is
a key regulatory step in the composition of the infiltrate: only
those cells in blood flow that are capable of participating in
tethering and rolling interactions will become tissue resi-
dents. Indeed, all ‘‘homing receptors’’ are effectors of Step
1 interactions. Thus, despite the selectivity implied by the
name, a broader view based on biophysics holds that a
homing receptor is, principally, a molecule specialized to
allow blood-borne cells to brake, contact and roll along the
endothelium at velocities below the prevailing hydrody-
namic flow.
E-Selectin, Cutaneous Lymphocyte Antigen
(CLA), and the Human ‘‘Skin Homing
Receptor’’
A number of well-characterized adhesion molecules serve
as mediators of Step 1 rolling interactions: the three
members of the selectin family (E-, P-, and L-selectin, also
known as CD62E, CD62P, and CD62L, respectively), the
‘‘hyaluronate receptor’’ CD44, and a small subset of the
integrin superfamily, principally VLA-4, a4b7, and LFA-1
(Berlin et al, 1993; Springer, 1994; Alon et al, 1995;
DeGrendele et al, 1996; Knorr and Dustin, 1997; Lichtman
et al, 1997; Sackstein, 1997; de Chateau et al, 2001). The
selectins are a family of integral membrane glycoproteins
that function as Ca2þ -dependent lectins in binding to
carbohydrate determinants expressed on their respective
ligands. E- and P-selectin are the ‘‘vascular’’ selectins,
which are typically inducible molecules expressed on
activated endothelium (and on platelets, for P-selectin),
yet are also expressed constitutively on bone marrow and
dermal microvasculature (Schweitzer et al, 1996; Frenette
et al, 1998; Weninger et al, 2000). L-selectin is the
‘‘leukocyte’’ selectin and, as mentioned above, is expressed
on granulocytes and monocytes, as well as on lympho-
cytes. The selectins are the most effective molecules in
mediating leukocyte tethering and rolling interactions on
endothelium in the hydrodynamic conditions of blood flow
and are capable of maintaining rolling at higher fluid shear
stresses than any other structures (Lawrence et al, 1997).
Moreover, the selectins bear the unique property of binding
optimally to their ligands under physiologic shear condi-
tions, and, in fact, L-selectin–ligand interactions require a
threshold shear level (Finger et al, 1996; Alon et al, 1997;
Lawrence et al, 1997).
The selectin ligands comprise a diverse group of
glycosylated molecules. Lymph node HEV express several
glycoprotein L-selectin ligands and each of these is
recognized by the mAb MECA79 (Streeter et al, 1988).
MECA 79 antigens (one of which is a specialized glycoform
of CD34 with restricted endothelial distribution) are sulfated
carbohydrates that are constitutively expressed on periph-
eral lymph node HEV, but can also be found at sites of
inflammation including skin (Sackstein, 1993; Lechleitner
et al, 1999; Mikulowska-Mennis et al, 2001; Renkonen et al,
2002). The principal leukocyte counter-receptor for the
vascular selectins is the glycoprotein known as P-selectin
glycoprotein ligand-1 (PSGL-1). PSGL-1 is a cell surface
mucin-like glycoprotein which can serve as a ligand for all
three selectins (Sako et al, 1993; Asa et al, 1995; Guyer et al,
1996; Spertini et al, 1996; Walcheck et al, 1996), however,
specialized post-translational modifications on the core
PSGL-1 protein backbone are necessary for ligand activity
for each of the selectins. In particular, the binding
determinants on PSGL-1 for both L- and P-selectin are
critically dependent on sulfation of tyrosines in the
N-terminal portion of the molecule (Sako et al, 1995; Li
et al, 1996), and PSGL-1 E-selectin ligand activity depends
on sialic acid and fucose modifications that are recognized
by the rat IgM mAb HECA452 (Duijvestijn et al, 1988), which
is directed against a sialyl Lewis X-like epitope (Berg et al,
1991). Inactive and active forms of PSGL-1 are expressed
on leukocytes and on hematopoietic progenitor cells (Alon
et al, 1994; Laszik et al, 1996; Lichtman et al, 1997).
On human lymphocytes, the expression of the HECA452
determinant on PSGL-1 is known as the CLA. Early studies
showed that the majority of lymphocytes in skin display
HECA452 reactivity but only a minority of lymphocytes in
non-cutaneous sites and in the circulation express this
marker. Subsequent studies showed that the CLA determi-
nant was found on a subset of skin-homing memory T cells,
and that the CLA epitope itself was involved in binding to
E-selectin (Picker et al, 1990; Berg et al, 1991; Picker et al,
1991). Later biochemical studies showed that the CLA
epitope is located on PSGL-1 (Fuhlbrigge et al, 1997), and
more recent studies have provided direct evidence that only
CLA(þ )PSGL-1 functions as an E-selectin ligand whereas
both CLA(þ ) and CLA() glycoforms of PSGL-1 can bind
P-selectin (Fuhlbrigge et al, 2002). The association between
HECA452-reactivity and lymphocyte trafficking to skin was
then operationally linked: just as L-selectin on lympho-
cytes mediates homing to lymph nodes that constitutively
express L-selectin ligands (MECA79 antigens) on HEV,
CLA(þ )PSGL-1 on memory T cells engages E-selectin (and
P-selectin), which is constitutively expressed on dermal
microvasculature (Weninger et al, 2000). Thus, CLA mod-
ifications on PSGL-1 promote migration of memory lym-
phocytes to skin.
In inflammation, the expression of both E- and P-selectin
are upregulated in dermal vessels, and, beyond their
constitutive function in promoting steady-state immunosur-
veillance, studies in mouse models have indicated that
these molecules play distinct and overlapping roles in
further recruiting T cells to inflamed skin (Tietz et al, 1998;
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Harari et al, 1999, Weninger et al, 2000). But depending on
the inflammatory stimulus and the mouse strain utilized,
E-selectin may play a more significant role than P-selectin in
mediating dermal leukocytic infiltrates (Ramos et al, 1997;
Tamaru et al, 1998; Hickey et al, 1999; Kulidjian et al, 2002;
Reinhardt et al, 2003). Interestingly, the binding determi-
nant(s) for E-selectin on murine leukocyte membranes is
undefined: the only evidence of CLA expression in mice has
been obtained on a T cell clone, and then only after
extensive antigen-specific activation of that clone (Borges
et al, 1997). In contrast, studies in human skin-SCID mouse
chimera models have definitively shown that CLA and
E-selectin direct recruitment of human lymphocytes into
human skin (Yan et al, 1994; Biedermann et al, 2002).
The Selectin Ligands of HSC: PSGL-1
and HCELL
As stated above, the bone marrow microvasculature is like
that of skin in that it displays constitutive expression of
E- and P-selectin (Schweitzer et al, 1996; Frenette et al,
1998). There is increasing evidence these molecules play
important roles in trafficking of primitive hematopoietic cells
into bone marrow (Frenette et al, 1998; Mazo et al, 1998;
Hidalgo et al, 2002; Katayama et al, 2003). Although the
identity of the true HSC is debated, for the purposes of this
review we will consider CD34þ cells lacking lineage-
specific markers (i.e., CD34þ /lineage cells) as the
representative population of HSC. Human HSC express
PSGL-1 and another selectin ligand, HCELL (Oxley and
Sackstein, 1994; Sackstein et al, 1997; Dimitroff et al, 2000,
2001a; Sackstein and Dimitroff, 2000). HCELL was initially
identified operationally as an L-selectin ligand, and was
distinguished from all other L-selectin ligands by a number
of biochemical features: (1) Sulfation-independent binding
activity; (2) functional resistance to O-sialoglycoprotease
digestion; (3) absence of MECA79 antigens; and (4)
L-selectin binding determinants that were expressed on
N-glycans rather than O-glycans (Oxley and Sackstein,
1994; Sackstein et al, 1997; Sackstein and Dimitroff, 2000).
Although initially considered to be a ‘‘novel’’ selectin ligand
by the above biochemical criteria, mass spectrometry
subsequently revealed that HCELL is not novel per se: it
is a glycoform of a well-recognized integral membrane
glycoprotein, CD44, that expresses the CLA epitope (i.e., is
recognized by mAb HECA452). In contrast to PSGL-1 that
displays CLA on O-glycans, however, the CLA determi-
nant(s) and the E-/L-selectin binding sites of HCELL are on
N-glycans.
Historically, CD44 has been known best for its role in
binding extracellular matrix elements, principally hyaluronic
acid (for which it is known as the ‘‘hyaluronic acid
receptor’’), but also fibronectin, collagen, and chondroitin
sulfate. Notably, at one time, CD44 was thought to be the
‘‘lymph node homing receptor’’ (Jalkanen et al, 1987), but it
was subsequently determined that it plays little role in
lymphocyte trafficking to lymphoid tissues but a key role in
lymphocyte migration to inflammatory sites (Rigby and
Dailey, 2000; Siegelman et al, 2000; Stoop et al, 2002). The
CD44 protein is expressed on essentially all hematopoietic
cells, as well as on epithelial cells, fibroblasts, and
endothelial cells, and its structure has been extensively
characterized. CD44 is an extremely heterogenous and
pleiotropic molecule, due to alternative splicing of ten
encoding exons and a variety of post-translational mod-
ifications (reviewed in Deguchi and Komada, 2000). But the
HCELL phenotype is present predominantly on the ‘‘stan-
dard’’ CD44 isoform (core m.w.  37,000) and migrates as
a glycoprotein of  98,000 m.w. on SDS-PAGE (Dimitroff
et al, 2000, 2001a).
PSGL-1 expressed on human HSC bears the CLA
epitope(s) and functions as a ligand for all three selectins.
But HCELL is  5-fold more avid an L-selectin ligand than
PSGL-1, and it expresses more potent E-selectin ligand
activity over a far wider shear range than PSGL-1 (Dimitroff
et al, 2001a, 2001b). Thus, HCELL is the principal E- and
L-selectin ligand of human HSC. Furthermore, whereas
PSGL-1 is expressed on immature and mature myeloid and
lymphoid cells, HCELL expression is characteristic only of
primitive hematopoietic cells, especially the earliest subset
of HSC lacking CD38 expression (CD34þ /CD38/lineage
cells) (Sackstein et al, 2001).
Besides PSGL-1 and HCELL, two other molecules
capable of serving as homing receptors are also character-
istically expressed on primitive human HSC, VLA-4, and
LFA-1 (Sackstein, 1993; Simmons et al, 1994). VLA-4 and
LFA-1 can serve in overlapping roles in rolling or firm
adherence, depending on the avidity state of the molecules
following cellular encounters with activating chemokines or
cytokines (Carlos and Harlan, 1994; Peled et al, 1999a).
LFA-1, however, is typically specialized to function solely in
firm adherence, and, depending on the cell type, VLA-4
function may also be restricted: e.g., in human HSC, VLA-4
functions mostly in tethering—not rolling—and only at low
shear stress under resting conditions, and activation leads
to only transient rolling with rapid transition to firm
adherence (Peled et al, 1999a). In this regard, initial
‘‘braking’’ and rolling of hematopoietic progenitors on bone
marrow endothelium most likely occurs through selectin
receptor–ligand interactions involving PSGL-1 and HCELL
with constitutively expressed E-selectin (Schweitzer et al,
1996) (and, in mice, P-selectin; Mazo et al, 1998, but
constitutive P-selectin expression in marrow sinusoids has
not been shown in humans). Results of recent studies using
human HSC in a xenogeneic (mouse) repopulation model
underscores the importance of selectins in the homing of
human HSC to the marrow (Peled et al, 1999a; Hidalgo et al,
2002; Katayama et al, 2003). E-selectin ligands and VLA-4
on HSC cooperate and represent the major adhesion
molecules mediating homing to bone marrow (Katayama
et al, 2003), but the engagement of E-selectin ligands is
more important for initiating tethering and primary rolling
interactions of human HSC (Peled et al, 1999a). The
contribution of VLA-4 in rolling may be a secondary effect,
potentiated by the native high levels of the chemokine SDF-
1 (CXCL12) in the marrow sinusoids coupled with the fact
that VCAM-1 is also constitutively expressed on bone
marrow endothelium (Mazo et al, 1998). Of all the homing
receptors expressed on HSC, HCELL is unique in that it is
expressed solely on HSC, whereas PSGL-1, VLA-4, and
LFA-1 are each characteristically expressed on a variety of
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immature and mature leukocytes. This restricted cellular
distribution and its marked potency for engagement of
natively expressed E-selectin on bone marrow endothelium
(Dimitroff et al, 2001a) suggest that HCELL functions as the
authentic ‘‘bone marrow homing receptor’’ on human HSC
(see Fig 2).
SDF-1 and E-Selectin: The ‘‘Roll’’ of HCELL
in Directing Homing of HSC to Bone Marrow
and Extramedullary Sites
For all cells emigrating the vasculature, the process of
transmigration is coordinated with the delivery of cells to
appropriate parenchymal microenvironments. Chemokines
are presented on the luminal surface at the tips of
endothelial microvilli, a topography that optimizes the
recognition of these molecules by cells in flow (Middleton
et al, 2002) and promotes the transition from rolling to firm
adherence. Following firm adherence, the transendothelial
movement and intraparenchymal migration are directed by
chemokine gradients. The major chemokine involved in
recruitment of HSC is SDF-1 (also known as CXCL12),
which binds to its cognate receptor CXCR4. The SDF-1/
CXCR4 axis is non-redundant, i.e., an exception among the
chemokine family in that one receptor binds one chemokine
and vice versa. This axis plays a critical role in development,
and mice made deficient in either CXCR4 or SDF-1 die
prenatally with deficits in hematopoiesis (due to lack of HSC
migration from the fetal liver to bone marrow during
embryogenesis), and neural and cardiac development
(Nagasawa et al, 1996; Ma et al, 1998). Postnatally, SDF-1
is produced constitutively in multiple organs by various
cells, including endothelial cells, tissue dendritic cells, and
bone marrow stromal cells (Pablos et al, 1999; Ponomaryov
et al, 2000; Muller et al, 2001). Studies in immune deficient
mice have shown that bone marrow homing of human HSC
is critically dependent on SDF-1/CXCR4 interactions (Peled
et al, 1999b), and in vitro transwell studies of human HSC
and human bone marrow endothlelial cells have revealed a
critical role for endothelial E-selectin expression in mediat-
ing SDF-1-driven transendothelial migration (Naiyer et al,
1999). Prior to transmigration, the E-selectin–ligand inter-
actions create optimal slow rolling velocities that enable
high efficiency recognition of chemokines such as SDF-1
(Ley et al, 1998; Peled et al, 1999a). Recent reports have
revealed concomitant upregulation of endothelial and
parenchymal SDF-1 expression in extramedullary sites
following chemical injury, viral inflammation, antigenic
challenge, irradiation, and ischemia (Gonzalo et al, 2000;
Pillarisetti and Gupta, 2001; Stumm et al, 2002; Kollet et al,
2003), and increased SDF-1 expression recruits human
HSC into the livers of immunodeficient mice following
hepatic injury (Kollet et al, 2003). Collectively, these data
indicate that whether expressed constitutively or induced
by local injury, SDF-1 and E-selectin play essential roles in
regulating the trafficking and localization of HSC (see Figs 2
and 3).
Besides sharing the distinction of constitutive E-selectin
expression, the microvascular endothelium of skin and bone
marrow each constitutively express SDF-1, and, just as with
hematopoietic stroma, Langerhans cells and dermal fibro-
blasts also constitutively express SDF-1 (Pablos et al, 1999;
Fedyk et al, 2001). Commensurate with these similarities
between skin and bone marrow, cutaneous hematopoiesis
has been observed in a variety of conditions of bone
marrow failure, myeloproliferative disorders, and hemato-
poietic stress (Bowden et al, 1989; Revenga et al, 2000;
Alter, 2002; Fernandez Acenero et al, 2003). Although
cutaneous hematopoiesis is a rare event, the fact that
blood cells are produced at all within the inhospitable
hematopoietic microenvironment of the skin is clear
evidence that the native expression of E-selectin and
SDF-1 are sufficient for recruitment of HSC to skin.
Furthermore, skin ‘‘chimerism’’ (i.e., identification of epithe-
lial cells of donor genotype) has been described following
clinical (myeloablative) HSC transplantation (Korbling et al,
2002). The finding that mesodermally derived HSC of the
donor contribute to epithelial lineages in the host offers
further evidence of the ‘‘plasticity’’ of stem cells. The low
level of skin chimerism observed following clinical HSC
transplantation may reflect the fact that these observations
Figure 2
Molecular components of hematopoietic stem cell (HSC)–bone
marrow endothelium interactions. The relevant molecules on the
HSC membrane (dots) and marrow endothelial membrane (dashes) that
form receptor–ligand interactions crucial for HSC homing to bone
marrow are depicted. See text for details.
Figure3
The multi-step model of hematopoietic stem cell (HSC) migration.
Schematic model of HSC migration to extramedullary tissues, showing
the central roles of endothelial E-selectin and of chemokine SDF-1 in
mediating transmigration and seeding of HSC within tissue micro-
environment(s). See text for details.
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have been made in atraumatic, intact skin. In an excisional
wound model in mice having previously received bone marrow
transplantation from syngeneic green fluorescent protein
(GFP)-expressing transgenics, significant numbers of differ-
entiated GFPþ cells were seen in the hair follicles, striated
muscles, sebaceous glands, and epidermis in host skin 21 d
after wounding (Badiavas et al, 2003). These and other
published data clearly show that the relative level of tissue
regeneration ascribable to effect(s) of colonized stem cells
(hematopoietic or mesenchymal) are correlated with the
degree of tissue injury, as if adequate ‘‘space’’ must be
present for engraftment and cell proliferation induced by
infiltrating stem cells (Petersen et al, 1999; Lagasse et al, 2000;
Orlic et al, 2001; Hess et al, 2002, 2003; Mangi et al, 2003).
Although rodent models suggest that both E- and
P-selectin contribute to directing leukocyte migration to
inflammatory sites, the primary endothelial selectin ex-
pressed in primates at sites of inflammation is E-selectin
(Yao et al, 1999). Moreover, as stated above, there are
important mouse strain-specific differences in the relative
expression of E- and P-selectin during inflammatory pro-
cesses. Based on these differences, results obtained from
murine models may not correlate with clinical conditions, and
studies of human cell trafficking in mice may only reveal the
minimum contribution(s) of E-selectin in the biology of
homing. Despite these limitations, studies in E-selectin
knockout mice have definitively shown that leukocyte
recruitment is dependent on slow rolling interactions
mediated by E-selectin under physiologic conditions (Ley et
al, 1998). The E-selectin-mediated slow rolling transit time
allows for optimal responses to the local milieu. In those
experimental situations where chemoattractants/chemokines
are presented in high concentrations (as by injection into a
localized site), the increased transit time in E-selectin-
deficient states is overcome by the overwhelming concen-
tration(s) of relevant chemoattractants such that the reduced
time of exposure is not a critical variable (Ley et al, 1998).
A number of important facts have emerged from existing
studies of human HSC homing in vivo using mouse–human
chimera models as surrogates of human physiology. From
these investigations, a model emerges in which recruitment
and retention of HSC to a given site are dependent on
recognition of SDF-1 gradients. Because SDF-1 expression
is characteristic of many tissues and is further upregulated
at sites of inflammation/ischemia, the limiting feature of
achieving HSC migration to/colonization of extramedullary
sites is the capacity of the circulating cells to undergo the
key Step 1 HSC–endothelial adhesive interactions essential
to recognition of this chemokine (Fig 3). Besides SDF-1,
HSC bear receptors for a variety of other chemokines
(Broxmeyer et al, 1999; Lee et al, 1999) and chemotactic
factors (Mohle et al, 2001), which, if expressed in a tissue-
or inflammation-specific manner, could synergise with SDF-
1 in directing HSC migration to appropriate target sites. The
selective recruitment of HSC would critically hinge, in any
case, on the capacity of the cells in blood flow to undergo
decelerating tethering and rolling interactions and ‘‘see’’ the
local deposits of these chemoattractants (Fig 3).
In order to optimize this process for infusion-based stem
cell therapies, HSC should be enriched for their capacity to
bind E-selectin. Accordingly, it would be important to select
HSC based on expression of HCELL, or, minimally,
CLA(þ )PSGL-1. Beyond this, in vitro manipulations to
increase the level of expression or the E-selectin ligand
activity of HCELL and/or PSGL-1 could be utilized to
enhance HSC homing capabilities. For T cells, methodolo-
gies to increase CLA expression by transfection of relevant
glycosyltransferases and by use of specific growth condi-
tions and cytokines have been described (Knibbs et al,
1996; Wagers et al, 1998; Lim et al, 1999; Fuhlbrigge et al,
2002), and each of these increases skin homing of these
cells. These data suggest that similar approaches could be
used to increase the expression of relevant sialofucosyl
modifications rendering amplified E-selectin ligand activity
on HSC. A more direct and immediate approach is to
develop reagents such as ‘‘activating’’ mAb that can
markedly enhance the capacity of HCELL and/or PSGL-1
to bind E-selectin. This strategy does not require cell culture
or extensive ex vivo manipulation(s) of HSC, and is currently
under intense study by our laboratory. All of the aforemen-
tioned strategies could be combined with angiographically
guided infusions of the HSC into the relevant vascular
bed(s) to attain a ‘‘first pass’’ effect and minimize migration
to non-target tissues. Clearly, validating the promise of the
clinical application of stem cell therapy for repair of
devastating tissue injury will depend on the rapid develop-
ment of methodologies to efficiently and safely place these
cells where they are most needed. Although the ideal
approach to achieve this end is not yet known, there is no
doubt that manipulation of the molecular mediators of the
physiologic trafficking of stem cells will literally open the
‘‘avenues’’ to safe and effective tissue regeneration.
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